PDF herunterladen
Klin Monbl Augenheilkd 2009; 226(1): 22-26
DOI: 10.1055/s-2008-1027615
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Wundheilungsmodulation nach filtrierenden Glaukomoperationen: Was kommt nach TGF-β?

Beyond TGF-β: Wound Healing Modulation in Filtering Glaucoma SurgeryT. Meyer-ter-Vehn1 , T. Klink1 , F. Grehn1 , G. Schlunck1
  • 1Augenklinik, Universitätsklinikum Würzburg
Weitere Informationen

Publikationsverlauf

Eingegangen: 1.4.2008

Angenommen: 12.6.2008

Publikationsdatum:
27. Januar 2009 (online)

Auch verfügbar auf
   Lizenzen und Reprints
Preview

Zusammenfassung

Die Vernarbung des operativ geschaffenen Kammerwasserabflusswegs ist das Hauptproblem der filtrierenden Glaukomchirurgie. Zytostatika können die Vernarbung hemmen, doch schränken unerwünschte Wirkungen ihren Einsatz ein. In dieser Übersicht werden Mechanismen und Besonderheiten der Wundheilung nach filtrierenden Glaukomoperationen erörtert und neuere Entwicklungen im Bereich der Wundheilungsmodulation vorgestellt. Der Wachstumsfaktor TGF-β spielt eine zentrale Rolle in der Wundheilung und Narbenbildung, weshalb ein Abfangen von TGF-β und die spezifische Blockade nachgeschalteter intrazellulärer Signale eine verbesserte Wundheilungsmodulation ermöglichen können. Zahlreiche neue Substanzklassen befinden sich in der präklinischen Erprobung und begründen die Hoffnung auf verbesserte Behandlungsmethoden durch eine erweiterte postoperative Kombinationstherapie.

Abstract

Conjunctival scarring remains the major problem in filtering glaucoma surgery. Antimetabolites afford a reduction of scar formation, but considerable side effects limit their application. Here, we review the mechanisms and peculiarities of wound healing following glaucoma surgery and report on new developments in the field of wound healing modulation. The growth factor TGF-β has a central role in wound healing and scarring. Therefore, novel concepts of wound healing modulation comprise scavenging of TGF-β and specific inhibition of disinct downstream intracellular signalling pathways. Several compounds have entered preclinical evaluation and offer new potential to modulate scarring in future combination therapies.

Schlüsselwörter

Glaukom - Wundheilung - TGF-beta

Key words

glaucoma - wound healing - TGF-beta

Literatur

  • 1 The Advanced Glaucoma Intervention Study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.  Am J Ophthalmol. 2000;  130 (4) 429-440
    Suche in Google Scholar
  • 2 Batterbury M, Wishart P K. Is high initial aqueous outflow of benefit in trabeculectomy?.  Eye. 1993;  7 (Pt 1) 109-112
    Suche in Google Scholar
  • 3 Baudouin C. et al . Efficacy of indomethacin 0.1 % and fluorometholone 0.1 % on conjunctival inflammation following chronic application of antiglaucomatous drugs.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 (11) 929-935
    Suche in Google Scholar
  • 4 Broadway D C. et al . Reversal of topical antiglaucoma medication effects on the conjunctiva.  Arch Ophthalmol. 1996;  114 (3) 262-267
    Suche in Google Scholar
  • 5 Chang L. et al . The role of the immune system in conjunctival wound healing after glaucoma surgery.  Surv Ophthalmol. 2000;  45 (1) 49-68
    Suche in Google Scholar
  • 6 Chen H S. et al . Control of filtering bleb structure through tissue bioengineering: An animal model.  Invest Ophthalmol Vis Sci. 2006;  47 (12) 5310-4
    Suche in Google Scholar
  • 7 Chicurel M E, Chen C S, Ingber D E. Cellular control lies in the balance of forces.  Curr Opin Cell Biol. 1998;  10 (2) 232-239
    Suche in Google Scholar
  • 8 Cordeiro M F. Beyond Mitomycin: TGF-beta and wound healing.  Prog Retin Eye Res. 2002;  21 (1) 75-89
    Suche in Google Scholar
  • 9 Cordeiro M F, Gay J A, Khaw P T. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.  Invest Ophthalmol Vis Sci. 1999;  40 (10) 2225-2234
    Suche in Google Scholar
  • 10 Cordeiro M F. et al . Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.  Gene Ther. 2003;  10 (1) 59-71
    Suche in Google Scholar
  • 11 Eibl K H. et al . Alkylphosphocholines: a new therapeutic option in glaucoma filtration surgery.  Invest Ophthalmol Vis Sci. 2004;  45 (8) 2619-2624
    Suche in Google Scholar
  • 12 Eming S A. et al . Accelerated wound closure in mice deficient for interleukin-10.  Am J Pathol. 2007;  170 (1) 188-202
    Suche in Google Scholar
  • 13 Ferguson M W, O’Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.  Philos Trans R Soc Lond B Biol Sci. 2004;  359 (1445) 839-850
    Suche in Google Scholar
  • 14 Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases.  J Pathol. 2003;  200 (4) 500-503
    Suche in Google Scholar
  • 15 Grehn F. Chirurgie des primären Offenwinkelglaukoms.  Klin Monatsbl Augenheilkd. 2008;  225 (1) 30-38
    Suche in Google Scholar
  • 16 Grehn F. et al . Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152.  Ophthalmology. 2007;  114 (10) 1831-1838
    Suche in Google Scholar
  • 17 Grisanti S. et al . Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study.  Invest Ophthalmol Vis Sci. 2005;  46 (1) 191-196
    Suche in Google Scholar
  • 18 Honjo M. et al . Potential role of Rho-associated protein kinase inhibitor Y-27 632 in glaucoma filtration surgery.  Invest Ophthalmol Vis Sci. 2007;  48 (12) 5549-5557
    Suche in Google Scholar
  • 19 Jendrossek V. et al . Intracellular mediators of erucylphosphocholine-induced apoptosis.  Oncogene. 2003;  22 (17) 2621-2631
    Suche in Google Scholar
  • 20 Khaw P. et al . A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy.  Ophthalmology. 2007;  114 (10) 1822-1830
    Suche in Google Scholar
  • 21 Klink T. et al . Nachsorge nach filtrierenden Glaukomoperationen.  Ophthalmologe. 2006;  103 (9) 815-823
    Suche in Google Scholar
  • 22 Klink T, Schrey S, Elsesser U. et al . Interobserver variability of the Wuerzburg bleb classification score.  Ophthalmologica. 2008;  222 im Druck
    Suche in Google Scholar
  • 23 Kumar S, Boehm J, Lee J C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.  Nat Rev Drug Discov. 2003;  2 (9) 717-726
    Suche in Google Scholar
  • 24 Lee J C. et al . p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials.  Pharmacol Ther. 1999;  82 (2 – 3) 389-397
    Suche in Google Scholar
  • 25 Marquardt D, Lieb W E, Grehn F. Intensified postoperative care versus conventional follow-up: a retrospective long-term analysis of 177 trabeculectomies.  Graefes Arch Clin Exp Ophthalmol. 2004;  242 (2) 106-113
    Suche in Google Scholar
  • 26 Martin P. et al . Wound healing in the PU.1 null mouse – tissue repair is not dependent on inflammatory cells.  Curr Biol. 2003;  13 (13) 1122-1128
    Suche in Google Scholar
  • 27 Mead A L. et al . Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.  Invest Ophthalmol Vis Sci. 2003;  44 (8) 3394-3401
    Suche in Google Scholar
  • 28 Meyer-ter-Vehn T. et al . P38 inhibitors prevent TGF-b-induced myofibroblast transdifferentiation in human tenon fibroblasts.  Invest Ophthalmol Vis Sci. 2006;  47 1500-1509
    Suche in Google Scholar
  • 29 Meyer-ter-Vehn T, Grehn F, Schlunck G. Localization of TGF-beta type II receptor and ED-A fibronectin in normal conjunctiva and feiled filtering blebs.  Mol Vis. 2008;  14 136-141
    Suche in Google Scholar
  • 30 Meyer-ter-Vehn T. et al . Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts.  Invest Ophthalmol Vis Sci. 2006;  47 (11) 4895-4904
    Suche in Google Scholar
  • 31 Mietz H, Jacobi P C, Krieglstein G K. Intraoperative episcleral versus postoperative topical application of mitomycin-C for trabeculectomies.  Ophthalmology. 2002;  109 (7) 1343-1349
    Suche in Google Scholar
  • 32 Mietz H, Krieglstein G K. Postoperative application of mitomycin c improves the complete success rate of primary trabeculectomy: a prospective, randomized trial.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 (11) 1429-1436
    Suche in Google Scholar
  • 33 Ng C P, Hinz B, Swartz M A. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro.  J Cell Sci. 2005;  118 (Pt 20) 4731-4739
    Suche in Google Scholar
  • 34 Pasquale L R. et al . Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye.  Invest Ophthalmol Vis Sci. 1993;  34 (1) 23-30
    Suche in Google Scholar
  • 35 Peters T. et al . Wound-healing defect of CD 18(–/–) mice due to a decrease in TGF-beta1 and myofibroblast differentiation.  Embo J. 2005;  24 (19) 3400-3410
    Suche in Google Scholar
  • 36 Picht G, Grehn F. Development of the filtering bleb after trabeculectomy. Classification, histopathology, wound healing process.  Ophthalmologe. 1998;  95 (5) W380-W387
    Suche in Google Scholar
  • 37 Picht G. et al . Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development.  Graefes Arch Clin Exp Ophthalmol. 2001;  239 (3) 199-207
    Suche in Google Scholar
  • 38 Schenk S, Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix.  Trends Cell Biol. 2003;  13 (7) 366-375
    Suche in Google Scholar
  • 39 Serini G. et al . The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1.  J Cell Biol. 1998;  142 (3) 873-881
    Suche in Google Scholar
  • 40 Shah M, Foreman D M, Ferguson M W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta.  Lancet. 1992;  339 (8787) 213-214
    Suche in Google Scholar
  • 41 Shah M, Foreman D M, Ferguson M W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring.  J Cell Sci. 1995;  108 (Pt 3) 985-1002
    Suche in Google Scholar
  • 42 Shaunak S. et al . Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation.  Nat Biotechnol. 2004;  22 (8) 977-984
    Suche in Google Scholar
  • 43 Siriwardena D. et al . Human antitransforming growth factor beta(2) monoclonal antibody – a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study.  Ophthalmology. 2002;  109 (3) 427-431
    Suche in Google Scholar
  • 44 Tomasek J J. et al . Myofibroblasts and mechano-regulation of connective tissue remodelling.  Nat Rev Mol Cell Biol. 2002;  3 (5) 349-363
    Suche in Google Scholar
  • 45 Tripathi R C. et al . Trabecular cells of the eye express messenger RNA for transforming growth factor-beta 1 and secrete this cytokine.  Invest Ophthalmol Vis Sci. 1993;  34 (8) 2562-2569
    Suche in Google Scholar
  • 46 Tripathi R C. et al . Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2.  Exp Eye Res. 1994;  59 (6) 723-727
    Suche in Google Scholar
  • 47 Tura A. et al . The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon’s capsule fibroblasts in vitro.  Invest Ophthalmol Vis Sci. 2007;  48 (5) 2152-2161
    Suche in Google Scholar
  • 48 Wong T T, Mead A L, Khaw P T. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery.  Invest Ophthalmol Vis Sci. 2005;  46 (6) 2018-2022
    Suche in Google Scholar
  • 49 Wong T T. et al . Matrix metalloproteinases in disease and repair processes in the anterior segment.  Surv Ophthalmol. 2002;  47 (3) 239-256
    Suche in Google Scholar
  • 50 Yamanaka O. et al . Inhibition of p38 MAP kinase suppresses fibrogenic reaction in conjunctiva in mice.  Mol Vis. 2007;  13 1730-1739
    Suche in Google Scholar

Dr. Günther Schlunck

Augenklinik und Poliklinik Universität Würzburg

Josef-Schneider-Str. 11

97080 Würzburg

Telefon: ++ 49/9 31/20 12 03 51

Fax: ++ 49/9 31/20 12 04 90

eMail: schlunck_g@klinik.uni-wuerzburg.de